Pricing Log in Create free account

Inhibikase Therapeutics, Inc. (IKT) vs Rocket Pharmaceuticals, Inc. (RCKT)

Inhibikase Therapeutics, Inc. and Rocket Pharmaceuticals, Inc. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Rocket Pharmaceuticals, Inc. are of similar size ($259.1M and $255.4M). Across the 11 metrics below, Inhibikase Therapeutics, Inc. leads on 6 and Rocket Pharmaceuticals, Inc. on 5.

Valuation

Metric IKT RCKT Biotechnology median
P/E n/m n/m 8.50
P/S 1,105.73 n/m 9.71
P/B 1.88 0.67 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.07 0.64
EV/Sales 495.30 n/m 9.21
Earnings yield (26.06%) (7.34%) (33.15%)
Free cash flow yield (14.80%) (69.93%) (25.50%)

Profitability

Metric IKT RCKT Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (51.96%) (4.77%) (56.36%)
Return on assets (48.04%) (4.09%) (48.04%)
Return on invested capital 0.00% (114.71%) 0.00%

Growth

Metric IKT RCKT Biotechnology median
Revenue growth (TTM) 110.93% — 6.02%
EPS growth (last fiscal year) 57.76% 26.37% 30.26%
Revenue growth, 5-year CAGR (42.21%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IKT RCKT Biotechnology median
Debt to equity 0.00 0.05 0.00
Current ratio 15.82 9.24 4.72
Net debt to EBITDA 3.44 0.77 0.96

Dividend

Metric IKT RCKT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IKT RCKT Biotechnology median
Market cap 255.35m 259.07m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack